Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $274.4 million.

  • Akebia Therapeutics' Shares Outstanding (Diluted Average) rose 3043.72% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year increase of 3043.72%. This contributed to the annual value of $210.9 million for FY2024, which is 1252.56% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Shares Outstanding (Diluted Average) is $274.4 million, which was up 3043.72% from $271.1 million recorded in Q2 2025.
  • Akebia Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $274.4 million during Q3 2025, with a 5-year trough of $153.8 million in Q1 2021.
  • For the 5-year period, Akebia Therapeutics' Shares Outstanding (Diluted Average) averaged around $198.0 million, with its median value being $187.5 million (2023).
  • In the last 5 years, Akebia Therapeutics' Shares Outstanding (Diluted Average) plummeted by 186.89% in 2023 and then skyrocketed by 3043.72% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Shares Outstanding (Diluted Average) stood at $165.9 million in 2021, then rose by 10.14% to $182.8 million in 2022, then grew by 2.56% to $187.5 million in 2023, then grew by 12.53% to $210.9 million in 2024, then surged by 30.07% to $274.4 million in 2025.
  • Its last three reported values are $274.4 million in Q3 2025, $271.1 million for Q2 2025, and $241.6 million during Q1 2025.